Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

“The first thing they see is the loose skin on their abdomen," says R. Brannon Claytor, a Bryn Mawr, Pa.-based plastic ...

Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.